应用倾向性评分方法分析脉血康胶囊对缺血性脑血管病治疗结局的影响
|
摘要
目的:探讨脉血康胶囊治疗缺血性脑血管病的治疗结局,了解脉血康胶囊对缺血性脑血管病治疗结局的影响,为临床合理用药提供借鉴。方法:选取基于全国20家大型三级甲等医院的电子医疗病历数据库,对使用和未使用脉血康胶囊的缺血性脑血管病患者按照一定的标准进行1∶1匹配。将数据库中治疗结局为"痊愈"和"好转"的重新合并定义为治疗有效,将"无效""死亡"和"其他"合并为治疗无效人群,通过倾向性评分的方法对重新合并后2组的治疗结局有效性进行比较。结果:匹配后使用脉血康胶囊患者组(A组)与未使用脉血康胶囊(B组)均为2 449例。在未控制混杂因素的情况下,2组的有效率差异有统计学意义(P <0. 05),A组较B组治疗效果好。通过3种Logistic回归分析方法分别进行了分析,均显示回归系数大于0,且差异有统计学意义(P <0. 05)。结论:使用脉血康胶囊的缺血性脑血管病患者较不使用该药的缺血性脑血管病患者的治疗有效率高,能提高缺血性脑血管病患者的临床疗效。
Objective: Based on the hospital electronic medical record database,to discuss the treatment outcome of the ischemic cerebrovascular disease with Maixuekang capsule,find out the effects of Maixuekang capsule on the treatment outcome of ischemic cerebrovascular disease,and provide reference for clinical rational drug use. Methods: This study was based on the database of electronic medical records of 20 large-scale tertiary-level hospitals across the country,and 1∶ 1 matching of patients with ischemic cerebrovascular disease who used and not used Maixuekang capsules according to certain standards. Recombination of treatment outcomes in the database with "recovery"and "improvement"were defined as treatment effectiveness,"invalidity""death",and"other"were merged into treatment-ineffective populations. The efficacy of the group's treatment outcomes was compared by propensity scores. Results: After matching,A group included 2449 cases treated with Maixuekang capsule and B group also included2449 cases treated with Maixuekang capsule. The simple chi-square test results showed that the effective rate of the two groups had significant statistical difference (P < 0. 05) in the absence of controlled confounding factors,and the treatment effect of group A was better than that of group B. Three logistic regression analysis methods were used for analysis. All showed that the regression coefficient was greater than 0,and all had statistical significance (P < 0. 01). Conclusion: Patients with ischemic cerebrovascular disease who used Maixuekang capsules are more effective than that those do not use this drug,and can improve the clinical efficacy of patients with ischemic cerebrovascular disease.
Objective: Based on the hospital electronic medical record database,to discuss the treatment outcome of the ischemic cerebrovascular disease with Maixuekang capsule,find out the effects of Maixuekang capsule on the treatment outcome of ischemic cerebrovascular disease,and provide reference for clinical rational drug use. Methods: This study was based on the database of electronic medical records of 20 large-scale tertiary-level hospitals across the country,and 1∶ 1 matching of patients with ischemic cerebrovascular disease who used and not used Maixuekang capsules according to certain standards. Recombination of treatment outcomes in the database with "recovery"and "improvement"were defined as treatment effectiveness,"invalidity""death",and"other"were merged into treatment-ineffective populations. The efficacy of the group's treatment outcomes was compared by propensity scores. Results: After matching,A group included 2449 cases treated with Maixuekang capsule and B group also included2449 cases treated with Maixuekang capsule. The simple chi-square test results showed that the effective rate of the two groups had significant statistical difference (P < 0. 05) in the absence of controlled confounding factors,and the treatment effect of group A was better than that of group B. Three logistic regression analysis methods were used for analysis. All showed that the regression coefficient was greater than 0,and all had statistical significance (P < 0. 01). Conclusion: Patients with ischemic cerebrovascular disease who used Maixuekang capsules are more effective than that those do not use this drug,and can improve the clinical efficacy of patients with ischemic cerebrovascular disease.
引文
[1]Furie KL,Kasner SE,Adams RJ,et al.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack:a guideline for healthcare professionals from the american heart association/american stroke association[J].Stroke,2011,42(1):227-276.
[2]孟胜喜,霍清萍.基于转化医学的中医药防治缺血性脑血管病研究[J].中西医结合心脑血管病杂志,2017,15(4):432-435.
[3]张东伟,谢晶军.脉血康胶囊辅助治疗急性脑梗死临床研究[J].浙江中西医结合杂志,2017,27(3):211-213.
[4]王国祥,郑慧芬,宗惠花,等.脉血康胶囊对脑梗死的疗效观察及对患者纤维蛋白原的影响[J].中国医院用药评价与分析,2012,12(5):447-449.
[5]郑文旭.脉血康胶囊对脑梗死恢复期患者的临床效果研究[J].中药药理与临床2015,31(4):247-249.
[6]郭晓庆,孙佳明,张辉.水蛭的化学成分与药理作用[J].吉林中医药,2015,35(1):47-50.
[7]袁咏梅,郝占芳,王素蛟,等.脉血康胶囊治疗短暂性脑缺血发作的临床分析[J].牡丹江医学院学报,2013,34(5):39-40.
[8]白静丽.脉血康胶囊对脑梗死患者的血流动力学变化及临床疗效观察[J].中西医结合心脑血管病杂志,2012,10(5):561-562.
[9]孙耀华.脉血康胶囊联合氟桂利嗪胶囊治疗椎-基底动脉供血不足疗效观察[J].临床医药文献(连续型电子期刊),2017,4(20):3898-3899.
[10]张素爱.脉血康胶囊治疗急性脑梗死的临床疗效[J].中西医结合心脑血管病杂志,2015,13(13):1549-1550,1551.
[11]胡萍,牛建平,宋叶华,等.脉血康胶囊对缺血性脑卒中病人LPA、hs-CRP及单核细胞表面TLR4表达的影响[J].中西医结合心脑血管病杂志,2017,15(7):854-858.
[12]杜立娟,谢雁鸣,王志飞,等.基于倾向性评分法的真实世界中喜炎平注射液对肾功能影响的分析[J].北京中医药,2016,35(3):202-206.
[13]李园,谢雁鸣,刘艳,等.运用倾向性评分方法探讨血栓心脉宁片对冠心病治疗结局的影响[J].中国中药杂志,2015,40(24):4791-4796.
[14]申浩,杨伟,谢雁鸣,等.运用倾向性评分的方法探讨联合使用灯盏细辛注射液对冠心病患者临床结局的影响[J].中国中药杂志,2013,38(18):3166-3171.
[15]艾青华,曾宪斌,谢雁鸣,等.基于倾向评分法研究真实世界参芪扶正注射液对肿瘤患者临床结局的影响[J].中国中药杂志,2013,38(18):3129-3136.
[2]孟胜喜,霍清萍.基于转化医学的中医药防治缺血性脑血管病研究[J].中西医结合心脑血管病杂志,2017,15(4):432-435.
[3]张东伟,谢晶军.脉血康胶囊辅助治疗急性脑梗死临床研究[J].浙江中西医结合杂志,2017,27(3):211-213.
[4]王国祥,郑慧芬,宗惠花,等.脉血康胶囊对脑梗死的疗效观察及对患者纤维蛋白原的影响[J].中国医院用药评价与分析,2012,12(5):447-449.
[5]郑文旭.脉血康胶囊对脑梗死恢复期患者的临床效果研究[J].中药药理与临床2015,31(4):247-249.
[6]郭晓庆,孙佳明,张辉.水蛭的化学成分与药理作用[J].吉林中医药,2015,35(1):47-50.
[7]袁咏梅,郝占芳,王素蛟,等.脉血康胶囊治疗短暂性脑缺血发作的临床分析[J].牡丹江医学院学报,2013,34(5):39-40.
[8]白静丽.脉血康胶囊对脑梗死患者的血流动力学变化及临床疗效观察[J].中西医结合心脑血管病杂志,2012,10(5):561-562.
[9]孙耀华.脉血康胶囊联合氟桂利嗪胶囊治疗椎-基底动脉供血不足疗效观察[J].临床医药文献(连续型电子期刊),2017,4(20):3898-3899.
[10]张素爱.脉血康胶囊治疗急性脑梗死的临床疗效[J].中西医结合心脑血管病杂志,2015,13(13):1549-1550,1551.
[11]胡萍,牛建平,宋叶华,等.脉血康胶囊对缺血性脑卒中病人LPA、hs-CRP及单核细胞表面TLR4表达的影响[J].中西医结合心脑血管病杂志,2017,15(7):854-858.
[12]杜立娟,谢雁鸣,王志飞,等.基于倾向性评分法的真实世界中喜炎平注射液对肾功能影响的分析[J].北京中医药,2016,35(3):202-206.
[13]李园,谢雁鸣,刘艳,等.运用倾向性评分方法探讨血栓心脉宁片对冠心病治疗结局的影响[J].中国中药杂志,2015,40(24):4791-4796.
[14]申浩,杨伟,谢雁鸣,等.运用倾向性评分的方法探讨联合使用灯盏细辛注射液对冠心病患者临床结局的影响[J].中国中药杂志,2013,38(18):3166-3171.
[15]艾青华,曾宪斌,谢雁鸣,等.基于倾向评分法研究真实世界参芪扶正注射液对肿瘤患者临床结局的影响[J].中国中药杂志,2013,38(18):3129-3136.